Abstract #5493: Antitumor effects by novel nitrone compound OKN007 in a rat C6 glioma model

Abstract

The prognosis of patients who are diagnosed with glioblastoma multiforme is very poor, due to the difficulty of an early and accurate diagnosis and the lack of currently efficient therapeutic compound. In a previous study, we demonstrated the efficiency of phenyl-tert-butylnitrone (PBN) as a potential anti-glioma drug in the pre-treatment of a rat C6 glioma implantation model. However, post-treatment of PBN had little effect for tumor regression compared with pre-treatment. Using the same model, we examined the effect of a novel Nitrone compound, OKN007 that is a structural analog of PBN. The rat glioma model was established by injecting C6 rat glioma cells (10⁶ cells in 10 uL) into the cerebral cortex of male Fischer 344 rats. Fifteen days later, OKN007 was orally administered through drinking water (0.015%, 17.5 mg/kg). The efficacy of OKN007 was assessed using tumor growth patterns and growth rates as determined by magnetic resonance (MR) imaging (T1/T2-weighted imaging) methods. MR results from OKN007 post-treated rats indicated a decrease in tumor volume and delay in tumor growth rate. OKN007 post-treatment was also significantly effective in increasing survival rate. Funds for this study were provided in part by the Oklahoma Medical Research Foundation (OMRF), and a grant (AR071-063) from the Oklahoma Center for the Advancement of Science & Technology (OCAST).

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5493.